Moffitt logo

Clinical Trials Search

Clinical Trial 19989

Cancer Type: Gastrointestinal Tumor
Interventions:Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Xeloda (capecitabine); capecitabine (); gemcitabine ()

Study Type: Treatment
Phase of Study: Phase III
Investigators:

  • Nainesh Parikh

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer

Summary

The study is a multi-center, open-label, randomized active-controlled study of patients with locally advanced pancreatic adenocarcinoma which is unresectable according to NCCN guidelines

Objective

Primary Objective: To compare the Overall Survival, from time of randomization until death, between patients receiving intra-arterial delivery of gemcitabine using the RenovoCath device for 16 weeks vs. continuation of IV gemcitabine and nab-paclitaxel for 16 weeks in those patients with stable disease following induction therapy with IV gemcitabine and nab-paclitaxel and radiation treatment for locally advanced pancreatic adenocarcinoma. Secondary Objectives: To compare in patients with locally advanced, unresectable pancreatic cancer treated with intra-arterial delivery of gemcitabine using the RenovoCath¿ device for 16 weeks vs. continuation of IV gemcitabine and nab-paclitaxel for 16 weeks: 1. Primary Endpoint for treatment received and unresected analysis populations 2. Progression free survival assessed according to RECIST 1.1 for all analysis populations 3. Objective response rate and duration of response 4. Health Related Quality of Life assessed with the EORTC, PCQL-10 and S-PGI questionnaires 5. Degree of peripheral neuropathy 6. Frequency of neutropenia requiring the use of filgrastim or other medications for white blood cell stimulation 7. Tolerability and safety of the combination

Inclusion Criteria

  • Histologically confirmed pancreatic adenocarcinoma with initial diagnosis within 6 weeks of consent
  • Locally advanced, unresectable disease, as defined by NCCN criteria
  • ECOG performance status 0-1
  • Age ≥ 18 years
  • Lab values as indicated per protocol
  • Life expectancy > 12 weeks
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 1 day prior to administration of the first dose of chemotherapy. Women of childbearing potential should only use highly effective methods of contraception during treatment and for up to 6 months following treatment cessation.
  • Provide written informed consent
  • Participants willing to participate in the study for at least 8 months

  • Exclusion Criteria

  • Any prior treatment for pancreatic cancer. If all other inclusion/exclusion criteria are met, and with prior written approval from sponsor, an exception may be granted for subjects who have had up to one prior treatment cycle with gemcitabine/nabpaclitaxel as this regimen is standard of care and part of the initial induction treatment on the protocol.
  • Any evidence of metastatic disease or another active malignancy within the past two years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
  • Prior biliary bypass surgery
  • Participants unable or unwilling to have their first randomized treatment within three weeks of the post induction imaging and within 5 weeks of their last induction treatment
  • Participants without baseline tumor imaging
  • Stenosis or occlusion in intended artery for treatment that precludes IA therapy as determined by CT or MRI
  • Tortuosity preventing the delivery of the guide sheath and or RenovoCath catheter to intended site as determined by CT or MRI
  • Inability to exclude major side branches in the area of the intended RenovoCath occlusion as determined by CT or MRI
  • No suitable artery with a diameter greater than 4mm in proximity of at least one side of the tumor as determined by CT or MRI
  • Participants with known HIV or active viral hepatitis
  • Severe infections within 4 weeks prior to the first study treatment, including but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia
  • Signs or symptoms of infection within 2 weeks prior to the first study treatment
  • Received oral or IV antibiotics for an infection within 2 weeks prior to the first study treatment. Participants receiving prophylactic antibiotics are eligible
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to gemcitabine or nab-paclitaxel
  • Any anti-cancer therapy including chemotherapy, hormonal therapy, or radiotherapy within 2 weeks prior to initiation of study treatment; or herbal therapy intended as anti-cancer therapy within 1 week prior to initiation of study treatment
  • Participants with uncontrolled seizures
  • Cardiovascular disease including unstable angina; therapy for life-threatening cardiac arrhythmia, myocardial infarction, stroke; or New York Heart Association (NYHA) Class III or IV congestive heart failure within the last 3 months prior to initiation of study treatment
  • Life-threatening visceral disease or other severe concurrent disease
  • Any major surgery prior initiation of study treatment.
  • Catheterization, endoscopy, stent or drain placement, within 48 hours (Note: laparoscopy without surgical intervention is not an exclusion criterion)
  • Minor surgery requiring light sedation within 2 weeks
  • Major surgery within 4 weeks
  • Women who are breastfeeding
  • Male or female participants of reproductive potential who do not agree to employ two highly effective and acceptable forms of contraception throughout their participation in the study and for 90 days after the last study treatment
  • Participants concurrently receiving any other investigational agents within 2 weeks prior to the first study treatment
  • Any psychiatric illness or social situations that would limit compliance with study requirements